Premium
The sleep effects of lurasidone: a placebo‐controlled cross‐over study using a 4‐h phase‐advance model of transient insomnia
Author(s) -
Krystal Andrew D.,
Zammit Gary
Publication year - 2016
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2533
Subject(s) - lurasidone , insomnia , placebo , transient (computer programming) , sleep (system call) , medicine , psychology , anesthesia , pharmacology , psychiatry , computer science , schizophrenia (object oriented programming) , alternative medicine , antipsychotic , pathology , operating system
Background Lurasidone, an atypical antipsychotic, is a potent 5‐HT 7 antagonist and D 2 , 5‐HT 2A antagonist, and 5‐HT 1A partial agonist. As such, lurasidone would be expected to modulate sleep and circadian function but there have been no human studies of the sleep effects of a 5‐HT 7 antagonist. The purpose of this study was to assess effects of lurasidone on sleep. Methods This was a cross‐over, polysomnographic study involving 54 healthy volunteers who underwent two treatment periods (order randomized) each consisting of two nights in the laboratory: Night 1—lights out at usual bedtime; Night 2–4‐h advance of sleep phase and randomization to either lurasidone 40 mg or placebo. The next morning impairment testing was carried out. Results Lurasidone significantly ( p < 0.05) increased total sleep time by an average of 28.4 min versus placebo, decreased wake time after sleep onset and wake time after the final awakening, and increased sleep efficiency. No other effects were found. Conclusions Lurasidone had a sleep maintenance effect without effects on sleep onset, rapid eye movement, or slow‐wave sleep. Lurasidone is likely to be beneficial to patients with disturbed sleep, particularly those with sleep maintenance problems. Copyright © 2016 John Wiley & Sons, Ltd.